When confirming antibody concentrations, sizing up proteins, or seeking the perfect formulation for a next-gen biologic, traditional approaches leave researchers tied to the lab bench for way too long ...
Biotherapeutic pipelines don’t just juggle monoclonal antibodies anymore, they need to be ready for protein conjugates like ADCs and for teeny tiny peptides. Even beyond new modalities, automation is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results